Richard J. Ranieri serves as Independent Director of the Company. Mr. Ranieri joined our Board of Directors in December 2017. Mr. Ranieri has more than 20 years of senior level biopharma human resource experience. He currently serves as a senior advisor to BioMarin Pharmaceutical Inc, and from September 2013 through December 2018, he served as executive vice president of human resources and corporate affairs for the company. Previously Mr. Ranieri served as executive vice president, human resources at Dendreon Pharmaceuticals from 2010 to 2013, and as executive vice president, human resources and administration at Sepracor, Inc. Earlier in his career, Mr. Ranieri served in executive positions at Neurocrine Biosciences, Inc., Genencor International, and SmithKline Beecham. He received a B.A. from Villanova University, and an M.A. in organizational behavior from Rider University.
As the Independent Director of Xencor Inc, the total compensation of Richard Ranieri at Xencor Inc is $294,295. There are 14 executives at Xencor Inc getting paid more, with Bassil Dahiyat having the highest compensation of $3,731,510.
Richard Ranieri is 67, he's been the Independent Director of Xencor Inc since 2017. There are no older and 18 younger executives at Xencor Inc.
Richard's mailing address filed with the SEC is C/O XENCOR, INC., 465 N HALSTEAD STREET, SUITE 200, PASADENA, CA, 91107.
Over the last 11 years, insiders at Xencor Inc have traded over $93,804,287 worth of Xencor Inc stock and bought 1,139,502 units worth $15,515,932 . The most active insiders traders include Capital, Llcstafford John S..., John S Iii Stafford, eJohn S Jr Stafford. On average, Xencor Inc executives and independent directors trade stock every 23 days with the average trade being worth of $779,296. The most recent stock trade was executed by John R Desjarlais on 9 July 2024, trading 50,000 units of XNCR stock currently worth $536,500.
antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product
Xencor Inc executives and other stock owners filed with the SEC include: